Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod IncfiledCriticalPfizer Prod Inc
Priority to CR6940ApriorityCriticalpatent/CR6940A/en
Publication of CR6940ApublicationCriticalpatent/CR6940A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se refiere a inhibidores de 5-espiropirimidin-2, 4,6-triona metaloproteinasas y a composiciones farmaceuticas y procedimientos de tratamiento en la inflamacion como el cancer y otras dolencias.It refers to inhibitors of 5-spiropyrimidin-2, 4,6-trione metalloproteinases and pharmaceutical compositions and methods of treatment in inflammation such as cancer and other ailments.
Compounds derived from imidazolidin-2-one, with inhibitory activity of 17alpha-hydroxylase / lyase-c17,20; pharmaceutical composition comprising them; and use in the treatment of inflammation or cancer, among others.
Compounds derived from thiophene or substituted thiazole, pi3k inhibitors; pharmaceutical composition; Useful in the treatment of cancer, inflammation and in the treatment of cardiovascular disorders.
Substituted n-hydroxy-3-phenylprop-2-enmide and n-hydroxy-3-phenylpropanamide derivative compounds; deacetylase enzyme inhibitors; its pharmaceutical composition; Useful in the treatment of cancer, tumors, psoriasis, Alzheimer's, among others.
Compounds derived from 6-phenyl-1h-imidazo [4,5-c] pyridine-4-carbonitrile, inhibitors of cathepsin s and cathepsin k; pharmaceutical composition; and use in the treatment of osteoporosis, atherosclerosis, inflammation, among other diseases.